Intuitive Surgical, Inc. (ISRG) is generating optimism among analysts, with Freedom Capital upgrading its rating to Buy and raising the price target to $610 due to elevated topline forecasts and the anticipated launch of da Vinci 5. Barclays also increased its price target to $712, maintaining an Overweight rating. The company specializes in robotic-assisted surgery with its da Vinci Surgical System and Ion endoluminal system.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Da Vinci 5 Sparks Optimism Around Intuitive Surgical, Inc. (ISRG)
Intuitive Surgical, Inc. (ISRG) is generating optimism among analysts, with Freedom Capital upgrading its rating to Buy and raising the price target to $610 due to elevated topline forecasts and the anticipated launch of da Vinci 5. Barclays also increased its price target to $712, maintaining an Overweight rating. The company specializes in robotic-assisted surgery with its da Vinci Surgical System and Ion endoluminal system.